Kombination von Obefazimod und Seinen Derivaten mit einem Tnf-Alpha-Hemmer
EP4785940
5. August 2026
Anmelder: ABIVAX 🇫🇷
Details
- Veröffentlichungs-Nr.
- EP4785940
- Anmeldetag
- 31. Januar 2025
- Veröffentlichung
- 5. August 2026
- Rechtsraum
- EP
Abstract
The present invention relates to pharmaceutical combinations, pharmaceutical compositions, kits comprising a compound of formula (I), a pharmaceutically acceptable salt thereof, a prodrug thereof, or a metabolite thereof, and a TNFα-inhibitor. The present invention also relates to said pharmaceutical combinations for use in the treatment of an inflammatory disease, disorder, or condition. The compound of formula (I) has the following formula: <img class="EMIRef" id="33a1e150-27c3-485d-b338-0320f6c08df3-ia01" />
Anmelder
- Firma
- ABIVAX
- Land
- 🇫🇷 Frankreich